B3GNT8

Across TCGA pan-cancer cohorts, B3GNT8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GNT8 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher B3GNT8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GNT8 expression acts as an unfavorable survival marker.

ACC, LUSC, and DLBC are the cancer types where B3GNT8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUSC	OS	Median	All	0.062	0.777	<.001	36	view →
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B3GNT8–ACC (DFS)

Open the ACC breakdown →